China's Role in Insilico Medicine's $2.5B Agreement with SK Biopharmaceuticals
In a groundbreaking development for the biopharmaceutical industry, the Hong Kong-listed AI drug discovery firm Insilico Medicine has clinched a monumental deal worth $2.5 billion with Korea's SK Biopharmaceuticals. The.....
Subscribe for Full Access!
Gain valuable sourcing and trade intelligence from our database of millions of data points spanning 20+ years!
